Physician

Syed Maseehur Rehman, MD

According to 2025 Medicare claims, Syed Rehman, MD (NPI: 1699775437) practices allergy/immunology in the Monroe, MI market, with the plurality of this provider's patient population coming from Monroe, MI. This provider's primary affiliated billing organization is ASTHMA & ALLERGY CENTER, INC (NPI: 1710174271; TIN: 383792860) and primary practice location at 43617-1177. Rehman is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Rehman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 142 traditional Medicare patients, billed 22,339 HCPCS/CPT codes, and received $586,067 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,423 prescription claims across 224 beneficiaries totaling $1,206,434 in drug costs, led by Takhzyro (Lanadelumab-Flyo). DME data shows 63 claims. Open Payments data shows 202 records totaling $404,774. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $176,870 to $1,206,434. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,804 to $736.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	154	36,842	$634,316
2016	202	47,593	$730,826
2017	208	62,668	$761,326
2018	172	65,299	$642,583
2019	171	60,227	$753,939
2020	190	49,151	$761,273
2021	167	40,989	$739,670
2022	140	38,124	$725,326
2023	131	17,260	$474,684
2024	142	22,339	$586,067

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	178	1,137	$176,870
2016	220	1,384	$253,524
2017	240	1,525	$506,003
2018	235	1,576	$462,682
2019	247	1,785	$783,167
2020	242	1,771	$640,711
2021	227	1,576	$504,083
2022	213	1,337	$403,195
2023	213	1,274	$567,383
2024	224	1,423	$1,206,434

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	95	$3,090
2016	N/R	89	$3,845
2017	29	139	$4,690
2018	N/R	12	$310
2019	13	63	$574
2020	11	113	$1,025
2021	N/R	40	$231
2022	N/R	44	$292
2023	N/R	53	$70,989
2024	N/R	63	$67,128

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	30	30	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	22	41	$88
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	111	231	$60
94010	Test to measure expiratory airflow and volume	65	147	$18
95004	Test for allergy using allergenic extract	33	1,751	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Takhzyro	Lanadelumab-Flyo	12	336	$588,009
Gamunex-C	Immune Globul G/Gly/Iga Avg 46	65	1,820	$123,807
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	118	5,790	$121,123
Gammagard Liquid	Immun Glob G(Igg)/Gly/Iga Ov50	11	308	$54,978
Nucala	Mepolizumab	11	308	$37,004

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1561	Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg	N	N/R	11	$34,073
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	N	N/R	14	$25,095
Q2052	Services, supplies and accessories used in the home for the administration of intravenous immune globulin (ivig)	N	N/R	24	$7,912
E0570	Nebulizer, with compressor	Y	N/R	14	$49

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	161	$42,248	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	41	$362,526	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Syed Maseehur Rehman, MD?

Tedicare shows public-source Medicare data for Syed Maseehur Rehman, MD (NPI 1699775437), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Syed Maseehur Rehman, MD have ACO affiliation data?

Syed Maseehur Rehman, MD is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Syed Maseehur Rehman, MD?

Syed Maseehur Rehman, MD is linked to ASTHMA & ALLERGY CENTER, INC (billing NPI 1710174271) in the available physician profile data.

Does Syed Maseehur Rehman, MD have Open Payments data?

Syed Maseehur Rehman, MD has 202 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.